Filing Flows

Filing Flows › Companies › Orthopediatrics › Cash flow

Orthopediatrics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$1.6M in Q3 2026 · $3.2M over twelve months

Operating cash flow$4.5M
Capital spending−$2.9M
Free cash flow+$1.6M
Cash conversion cycle649 days

Analysis

In Q3 2026, Orthopediatrics generated $4.5M of operating cash flow and spent $2.9M on capital projects, leaving free cash flow of $1.6M. That is $5.0M more than in Q3 2025 (−$3.4M).

Over the twelve months to Sep 30, 2026, operating cash flow was $12.5M; the largest uses were capital spending ($9.3M), other financing ($3.1M), other investing ($880K); the cash balance fell by $1.0M.

Operating cash flow was $4.5M against net income of −$5.9M. The largest differences: depreciation & amortization +$5.6M, stock-based pay +$4.4M, inventory −$2.4M.

Its cash conversion cycle was 649 days (receivables 76 + inventory 688 − payables 115).

Free cash flow

Orthopediatrics: free cash flow by quarterOrthopediatrics: free cash flow by quarter−$3.7MQ4 2024−$8.4MQ1 2025−$13.9MQ2 2025−$3.4MQ3 2025$9.7MQ4 2025−$5.0MQ1 2026−$3.1MQ2 2026$1.6MQ3 2026
Operating cash flow less capital spending.
Orthopediatrics: operating cash flow against capital spendingOrthopediatrics: operating cash flow against capital spendingOperating cash flowCapital spending−$4.0M−$262KQ4 2024−$4.2M$4.2MQ1 2025−$10.5M$3.4MQ2 2025−$581K$2.8MQ3 2025$10.3M$599KQ4 2025−$3.3M$1.8MQ1 2026$928K$4.0MQ2 2026$4.5M$2.9MQ3 2026
Latest (Q3 2026): Operating cash flow $4.5M, Capital spending $2.9M.

Capital allocation, year by year

Orthopediatrics: where the cash came from (up) and went (down), by fiscal yearOrthopediatrics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$13.1MFY2021: Net borrowing −$131KFY2021: Shares issued $137KFY2021: Capital spending −$8.1M$137KFY2021FY2022: Operating cash flow −$21.8MFY2022: Net borrowing $30.9MFY2022: Shares issued $139MFY2022: Capital spending −$10.0M$170MFY2022FY2023: Operating cash flow −$27.0MFY2023: Net borrowing $9.4MFY2023: Shares issued $21KFY2023: Capital spending −$16.9M$9.4MFY2023FY2024: Operating cash flow −$27.0MFY2024: Net borrowing $61.3MFY2024: Capital spending −$14.3MFY2024: Acquisitions −$20.2M$61.3MFY2024FY2025: Operating cash flow −$4.9MFY2025: Net borrowing $24.8MFY2025: Capital spending −$11.1M$24.8MFY2025
Over these 5 years operating cash flow totalled −$93.8M; the largest uses were operating cash flow ($93.8M) and capital spending ($60.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$44.2M
Debt$105M
Net debt$60.4M
Due within a year$1.9M

Orthopediatrics funds itself: free cash flow was $3.2M over the last twelve months, and $44.2M of cash and investments stands against $105M of debt ($1.9M due within a year, 23.9× covered by cash).

Orthopediatrics: debt maturities by year (FY2025)Orthopediatrics: debt maturities by year (FY2025)$1.9MYear 1$3.0MYear 2$140KYear 3$51.0MYear 4$50.0MYear 5
Principal due in each year as disclosed in the annual report, against $44.2M of cash and investments now.

Where the cash came from and went

Orthopediatrics: sources (+) and uses (−) of cash, Q3 2026Orthopediatrics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$4.5MCapital spending−$2.9MOther financing−$1.5MOther investing−$1.2MCash drawn (+) / kept (−)$1.2MNet borrowing (+) / repaid (−)−$42KExchange rates−$32K
Orthopediatrics: sources (+) and uses (−) of cash, TTM to Q3 2026Orthopediatrics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$12.5MCapital spending−$9.3MOther financing−$3.1MCash drawn (+) / kept (−)$1.0MOther investing−$880KNet borrowing (+) / repaid (−)−$166KExchange rates−$36K

From profit to cash

Orthopediatrics: net income to operating cash flow, Q3 2026Orthopediatrics: net income to operating cash flow, Q3 2026Net income−$5.9MDepreciation & amortization$5.6MStock-based pay$4.4MDeferred taxes−$311KInventory−$2.4MPayables$2.2MAccrued liabilities−$393KPrepaid and other assets−$780KOther operating capital−$205KOperating cash flow$4.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202676688115649
Q2 202674681105650
Q1 202682755108728
Q4 20257873272738
Q3 20257973257753
Q2 20257365372655
Q1 20257475373754
Q4 20247464055659

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q3 2026$4.5M−$2.9M−$42K$1.2M$1.6M
Q2 2026$928K−$4.0M−$44K−$4.8M−$3.1M
Q1 2026−$3.3M−$1.8M−$41K$7.4M−$5.0M
Q4 2025$10.3M−$599K—−$2.7M$9.7M
Q3 2025−$581K−$2.8M−$41K$27.7M−$3.4M
Q2 2025−$10.5M−$3.4M−$39K−$11.2M−$13.9M
Q1 2025−$4.2M−$4.2M−$39K$10.3M−$8.4M
Q4 2024−$4.0M$262K—$7.3M−$3.7M

Orthopediatrics: income statement and cash flow

Orthopediatrics, Q3 2026: revenue $72.7M (+19% year over year), operating margin -5.8%. The chart follows the revenue to costs, profit and cash.

Orthopediatrics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.